Artiva Biotherapeutics Inc’s filing revealed that its Director RA CAPITAL MANAGEMENT, L.P. acquired Company’s shares for reported $100.0 million on Jul 22 ’24. In the deal valued at $12.00 per share,8,333,333 shares were bought. As a result of this transaction, RA CAPITAL MANAGEMENT, L.P. now holds 8,693,579 shares worth roughly $87.63 million.
Then, 5AM Partners VI, LLC bought 833,333 shares, generating $9,999,996 in total proceeds. Upon buying the shares at $12.00, the 10% Owner now owns 1,182,054 shares.
Before that, venBio Global Strategic Fund I bought 416,666 shares. Artiva Biotherapeutics Inc shares valued at $4,999,992 were divested by the 10% Owner at a price of $12.00 per share. As a result of the transaction, venBio Global Strategic Fund I now holds 1,936,637 shares, worth roughly $19.52 million.
H.C. Wainwright initiated its Artiva Biotherapeutics Inc [ARTV] rating to a Buy in a research note published on December 30, 2024; the price target was $20. A number of analysts have revised their coverage, including Wedbush’s analysts, who began to cover the stock in mid August with a ‘”an Outperform”‘ rating. TD Cowen began covering ARTV with “Buy” recommendation on August 13, 2024. Needham started covering the stock on August 13, 2024. It rated ARTV as “a Buy”.
Price Performance Review of ARTV
On Tuesday, Artiva Biotherapeutics Inc [NASDAQ:ARTV] saw its stock fall -4.73% to $10.08. Over the last five days, the stock has lost -3.82%. Artiva Biotherapeutics Inc shares have fallen nearly -16.00% since the year began.
Levels Of Support And Resistance For ARTV Stock
The 24-hour chart illustrates a support level at 9.69, which if violated will result in even more drops to 9.29. On the upside, there is a resistance level at 10.79. A further resistance level may holdings at 11.49. The Relative Strength Index (RSI) on the 14-day chart is 41.71, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.19, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 88.44%. Stochastics %K at 21.77% indicates the stock is a holding.
How much short interest is there in Artiva Biotherapeutics Inc?
A steep rise in short interest was recorded in Artiva Biotherapeutics Inc stocks on 2024-12-13, growing by 87901.0 shares to a total of 1.02 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 0.94 million shares. There was a rise of 8.59%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 13, 2024 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $21 price target.
